| Code | CSB-RA011662MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to mepolizumab, targeting human interleukin-5 (IL-5), a key cytokine in eosinophil biology. IL-5 functions as the primary regulator of eosinophil production, differentiation, activation, and survival, playing a central role in type 2 inflammatory responses. Dysregulated IL-5 signaling contributes to eosinophil-mediated pathologies including severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyposis. By binding to IL-5, this antibody prevents interaction with the IL-5 receptor on eosinophils and basophils, thereby inhibiting downstream inflammatory cascades.
Mepolizumab, the reference therapeutic antibody, is a humanized IgG1 kappa monoclonal antibody that has been extensively studied for its mechanism of eosinophil depletion in allergic and inflammatory conditions. This biosimilar provides researchers with a valuable tool for investigating IL-5-mediated immune responses, eosinophil function, and potential therapeutic interventions in eosinophilic disorders. It enables studies of cytokine neutralization mechanisms and type 2 immunity pathways in various experimental models.
There are currently no reviews for this product.